Compare Pfizer Inc (PFE) vs Tempus AI (TEM) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

Tempus AI (TEM) trades at $48.41, down 7.74% amid market reaction to its $1.5 billion acquisition of Personalis. The stock shows bearish technical signals with negative moving averages and oversold RSI levels. Fundamentally, the company maintains strong revenue growth ($1.27B in 2025) but faces significant losses (-$245M net income) and negative margins. Recent news highlights strategic expansion in cancer diagnostics through AI-driven platforms.

Despite analyst optimism (61.5% buy ratings, $68.50 target), TEM faces execution risks from the major acquisition and persistent profitability challenges. The stock's current discount to target offers potential upside if integration succeeds, but high cash burn and competitive pressures require careful monitoring for investors considering entry at these levels.